Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
1. A pharmaceutical composition comprising a human tear lipocalin mutein specific for IL-4Rα, or a fragment or variant thereof or a fusion protein or conjugate thereof, at a concentration ranging from 0.01 mg/ml to 100 mg/ml in a solution, wherein the said solution comprises:
a. a pH level between about 5.5 and 8.0,
b. an osmolality value between about 150 and 550 mOsm/L, and
c. an ion concentration between about 31 and 300 mM of chloride as a permeant anion, and wherein the pharmaceutical composition comprises an aerosol obtained by nebulization of the solution and the aerosol has a mass median aerodynamic diameter (MMAD) ranging from 1μm to 10 μm.
2. A pharmaceutical composition according to claim 1 , wherein said solution has a viscosity value less than about 1.5 cp.
3. A pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition has a concentration level of the human tear lipocalin mutein specific for IL-4Rα or a fragment or variant thereof or a fusion protein or conjugate thereof selected from the group consisting of: 0.05 mg/ml to 50 mg/ml, 0.1 mg/ml to 50 mg/ml, 0.05 mg/ml to 25 mg/ml, 0.1 mg/ml to 25 mg/ml, 0.05 mg/ml to 15 mg/ml, 0.1 mg/ml to 15 mg/ml, 0.05 mg/ml to 10 mg/ml, and 0.1 mg/ml to 10 mg/ml.
4. A pharmaceutical composition according to claim 1 , wherein said solution has an adjusted pH selected from the group consisting of between 5.5 and 8.0, between 6.0 and 8.0, between 6.0 and 7.5, between 5.5 and 7.5, between 6.0 and 7.0 and between 6.5 and 7.5.
5. A pharmaceutical composition according to claim 1 , wherein said solution has an osmolality value selected from the group consisting of: between about 150 and 550 mOsm/kg, between about 150 and 500 mOsm/kg, between about 200 and 550 mOsm/kg, between about 200 and 500 mOsm/kg, between about 200 and 450 mOsm/kg and between about 150 and 450 mOsm/kg.
6. A pharmaceutical composition according to claim 1 , wherein said solution has an ion concentration of chloride as a permeant anion from the group consisting of between 31 and 300 mM, between 50 and 200 mM, between 50 and 300 mM, between 50 and 150 mM, 100 and 200 mM, between 100 and 300 mM, between 100 and 250 mM, between 150 and 250 mM, between 150 and 300 mM and between 200 and 300 mM.
7. A pharmaceutical composition according to claim 1 , wherein said solution has a viscosity selected from the group consisting of between 0 and 1.5 cp, between 0 and 1.0 cp, 0 and 0.5 cp, between 0.5 and 1.0 cp, between 0.5 and 1.5 cp and between 1.0 and 1.5 cp.
8. A pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises an aerosol obtained by nebulization of the solution, wherein the aerosol has a mass median aerodynamic diameter (MMAD) selected from the group consisting of between 1 μm to 10 μm, between 2 μm to 8 μm, between 2 μm to 5 μm, between 1.5 μm to 4 μm, between 3 μm to 4.5 μm and between 2.5 μm to 3.5 μm.
9. A pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises an aerosol obtained by nebulization of the solution using an electronic nebulizer, jet, ultrasonic, or with a vibrating perforated membrane or a vibrating mesh nebulizer.
10. A pharmaceutical composition according to claim 1 , wherein said the human tear lipocalin mutein specific for IL-4Rα or a fragment or variant thereof or a fusion protein or conjugate thereof maintains its functional and structural integrity upon and after nebulization.
11. A pharmaceutical composition according to claim 1 , wherein said the human tear lipocalin mutein specific for IL-4Rα or a fragment or variant thereof or a fusion protein or conjugate thereof remains monomeric upon and after nebulization.
12. A pharmaceutical composition according to claim 1 , wherein said lipocalin mutein is capable of inhibiting IL-4 and/or IL-13 from binding to their respective receptors, wherein said lipocalin mutein is capable of exhibiting in vivo therapeutic activity in the subject, wherein said lipocalin mutein has a mutated amino acid at any one or more amino acids positions corresponding to position(s) 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), and wherein said lipocalin mutein has at least 75% identity to the sequence of mature human tear lipocalin (SEQ ID NO: 1).
13. The pharmaceutical composition according to claim 1 , wherein said lipocalin mutein has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6.
14. The pharmaceutical composition according to claim 1 , wherein said lipocalin mutein has at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 6.
15. The pharmaceutical composition according to claim 1 , wherein said lipocalin mutein is capable of inhibiting in vivo human IL-13 induced transcript Ccl11 (eotaxin).
16. The pharmaceutical composition according to claim 1 , wherein said lipocalin mutein is more potent than an IL-4 mutant (R121D, Y124D) when inhibiting human IL-13 induced transcript Ccl11 (eotaxin) in vivo.
17. The pharmaceutical composition according to claim 1 , wherein said lipocalin mutein is capable of exhibiting a functional activity as good as an anti-IL-4Rα monoclonal antibody AMG 317 having the variable light and heavy chain sequence as shown in SEQ ID NO: 14 and 15, respectively, wherein said lipocalin mutein is capable of inhibiting IL-13-induced goblet cell metaplasia as good as the anti-IL-4Rα monoclonal antibody.
18. The pharmaceutical composition according to claim 1 , which is adapted for delivery by inhalation within 1-3 minutes.
19. The pharmaceutical composition according to claim 18 , wherein the delivery by inhalation is locally to the lung.
20. A method of treating or ameliorating a lung disorder that is related to the immune system, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 1 via nebulization.